[go: up one dir, main page]

DK1802274T3 - Anvendelse af cannabidiol i inhibitionen af hjernetumorcellemigration - Google Patents

Anvendelse af cannabidiol i inhibitionen af hjernetumorcellemigration

Info

Publication number
DK1802274T3
DK1802274T3 DK05788521T DK05788521T DK1802274T3 DK 1802274 T3 DK1802274 T3 DK 1802274T3 DK 05788521 T DK05788521 T DK 05788521T DK 05788521 T DK05788521 T DK 05788521T DK 1802274 T3 DK1802274 T3 DK 1802274T3
Authority
DK
Denmark
Prior art keywords
inhibition
cell migration
cannabidiol
tumor cell
brain tumor
Prior art date
Application number
DK05788521T
Other languages
Danish (da)
English (en)
Inventor
Brian Whittle
Daniela Parolaro
Original Assignee
Gw Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gw Pharma Ltd filed Critical Gw Pharma Ltd
Application granted granted Critical
Publication of DK1802274T3 publication Critical patent/DK1802274T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK05788521T 2004-10-01 2005-09-30 Anvendelse af cannabidiol i inhibitionen af hjernetumorcellemigration DK1802274T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0421900A GB2418612A (en) 2004-10-01 2004-10-01 Inhibition of tumour cell migration with cannabinoids
PCT/GB2005/003793 WO2006037981A1 (fr) 2004-10-01 2005-09-30 Inhibition de la migration de cellules tumorales

Publications (1)

Publication Number Publication Date
DK1802274T3 true DK1802274T3 (da) 2009-02-02

Family

ID=33427951

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05788521T DK1802274T3 (da) 2004-10-01 2005-09-30 Anvendelse af cannabidiol i inhibitionen af hjernetumorcellemigration

Country Status (10)

Country Link
US (3) US20080262099A1 (fr)
EP (1) EP1802274B1 (fr)
JP (5) JP2008514687A (fr)
AT (1) ATE408412T1 (fr)
CA (1) CA2582289C (fr)
DE (1) DE602005009852D1 (fr)
DK (1) DK1802274T3 (fr)
ES (1) ES2313414T3 (fr)
GB (1) GB2418612A (fr)
WO (1) WO2006037981A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
WO2008144475A1 (fr) * 2007-05-17 2008-11-27 California Pacific Medical Center Procédés et compositions pour traiter le cancer
GB2450493A (en) * 2007-06-25 2008-12-31 Gw Pharma Ltd Cannabigerol for use in treatment of diseases benefiting from agonism of CB1 and CB2 cannabinoid receptors
ES2359168T3 (es) * 2007-10-02 2011-05-19 Vivacell Biotechnology España S.L. Composición que comprende cannabinoides no psicotrópicos para el tratamiento de enfermedades antiinflamatorias.
GB0808668D0 (en) * 2008-05-13 2008-06-18 Univ Aberdeen Materials and methods relating to a G-protein coupled receptor
GB2460672B (en) * 2008-06-04 2012-01-04 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents
GB2478074B (en) * 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
KR20120111125A (ko) * 2011-03-31 2012-10-10 주식회사한국전통의학연구소 마자인 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
GB2494461A (en) * 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
CA3012383C (fr) 2013-02-28 2021-03-02 Teewinot Technologies Limited Biosyntheses de cannabinoides
GB2516814B (en) * 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
US9220294B2 (en) 2014-02-11 2015-12-29 Timothy McCullough Methods and devices using cannabis vapors
US10821240B2 (en) 2014-02-11 2020-11-03 Vapor Cartridge Technology Llc Methods and drug delivery devices using cannabis
US9380813B2 (en) 2014-02-11 2016-07-05 Timothy McCullough Drug delivery system and method
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
US9186386B2 (en) 2014-04-17 2015-11-17 Gary J. Speier Pharmaceutical composition and method of manufacturing
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
JP6622793B2 (ja) 2014-08-25 2019-12-18 ティーウィノット テクノロジーズ リミテッド カンナビノイド化合物を同時作製する装置及び方法
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
CA2974292C (fr) 2015-01-31 2024-04-16 Constance Therapeutics, Inc. Procedes de preparation d'extraits d'huile de cannabis et compositions
MX382296B (es) 2015-05-27 2025-03-13 Cannabics Pharmaceuticals Inc Sistema y método para la detección de alto rendimiento de células cancerígenas.
WO2017091764A1 (fr) 2015-11-24 2017-06-01 Constance Therapeutics, Inc. Compositions d'huile de cannabis et leurs procédés de préparation
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
BR112019001852A2 (pt) 2016-08-03 2019-05-07 Zelda Therapeutics Operations Pty Ltd composição de cannabis
KR20190034576A (ko) 2016-08-03 2019-04-02 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
US10058531B1 (en) 2017-06-01 2018-08-28 Spartak LLC Dosage delivery film
KR20200104278A (ko) 2017-06-19 2020-09-03 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 수면 장애 조성물 및 그의 치료
EP4030941A1 (fr) 2019-09-16 2022-07-27 Vapor Cartridge Technology LLC Système d'administration de médicament avec substrats empilables
CA3187303A1 (fr) 2020-07-28 2022-02-03 Impello Biosciences, Inc. Procedes et compositions pour modifier des metabolites secondaires dans des plantes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2164584A1 (es) * 2000-02-11 2002-02-16 Univ Madrid Complutense Terapia con cannabinoides para el tratamiento de tumores cerebrales.
US20040039048A1 (en) * 2000-02-11 2004-02-26 Manuel Guzman Pastor Therapy with cannabinoid compounds for the treatment of brain tumors
US6448288B1 (en) * 2000-05-17 2002-09-10 University Of Massachusetts Cannabinoid drugs
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
US6730330B2 (en) * 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
CZ306277B6 (cs) * 2001-02-14 2016-11-09 Gw Pharma Limited Pumpičkou aktivovaná kapalná sprejová formulace
GB2377218A (en) * 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products

Also Published As

Publication number Publication date
EP1802274B1 (fr) 2008-09-17
US20190255011A1 (en) 2019-08-22
WO2006037981A8 (fr) 2006-06-01
JP2017031190A (ja) 2017-02-09
US20080262099A1 (en) 2008-10-23
JP6280489B2 (ja) 2018-02-14
JP2008514687A (ja) 2008-05-08
JP2014094960A (ja) 2014-05-22
WO2006037981A1 (fr) 2006-04-13
EP1802274A1 (fr) 2007-07-04
JP2012131803A (ja) 2012-07-12
CA2582289A1 (fr) 2006-04-13
GB0421900D0 (en) 2004-11-03
GB2418612A (en) 2006-04-05
ES2313414T3 (es) 2009-03-01
CA2582289C (fr) 2014-10-14
JP2015038137A (ja) 2015-02-26
DE602005009852D1 (de) 2008-10-30
US20120225136A1 (en) 2012-09-06
ATE408412T1 (de) 2008-10-15

Similar Documents

Publication Publication Date Title
DK1802274T3 (da) Anvendelse af cannabidiol i inhibitionen af hjernetumorcellemigration
NL301145I2 (nl) Tirbanibulin
BRPI0518228A (pt) inibidores de cinesina mitótica e métodos de uso destes
EA200802213A1 (ru) Способы лечения заболеваний крови
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
PL2192911T3 (pl) Roślinny ekstrakt z konopi ubogich w THC do leczenia chorób
CR11731A (es) Composiciones y procedimientos para su preparación y uso
ATE424159T1 (de) Katheter
CL2008002006A1 (es) Compuestos derivados de morfolin pirimidina, composicion farmaceutica, y su uso como inhibidores de la m-tor-quinasa para el tratamiento de l a inflamacion, cancer, enfermedades inmunes, enfermedad obstructiva pulmonar, enfermedad cardiovascular.
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
BR112014026703A2 (pt) inibidores de dna-pk
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
EP2513343A4 (fr) Procédés et compositions pour traiter l'inflammation de la peau
CL2010001406A1 (es) Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion.
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
CL2008002185A1 (es) Compuestos derivados de pirimidina, inhibidores de fosfatidilinositol-3-cinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades resapiratorias, alergias, inflamacion, cancer, entre otras enfermedades.
CR11423A (es) NUEVOS INHIBIDORES DE sEH Y SU USO
UY29036A1 (es) Derivados de oxopiperidina, su preparacion y su aplicacion en terapeutica
DOP2006000024A (es) Tiazolidinonas, su preparación y su uso como medicamento
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
NI201200103A (es) NUEVOS DERIVADOS ( HETEROCICLO - TETRAHIDRO - PIRIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y ( HETEROCICLO - DIHIDRO - PIRROLIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y SU UTILIZACIÓN COMO INHIBIDORES DE p75
WO2010042600A3 (fr) Agents thérapeutiques photo-activables et procédés d'utilisation
DK2285367T3 (da) Farmaceutiske sammensætninger til behandling af vorter